coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Goldstone PCN, Brighton and Hove (LAD) · Health Inequalities Profile

    PCN U46447 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 3 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    80,554

    Registered population

    72.3% aged 18–64

    12.8%

    Aged 65+

    ICB 21.9% · England 17.9%

    15.2%

    Ethnic minority (non-White)

    5.0% Asian · England 9.6%

    3.5%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    ~2,319

    Core20 residents (est.)

    Resident basis; registered basis ~2,678 · see page 3

    7,455

    Hypertension register

    +5.70% in 3 yrs · England +5.60%

    1,333

    SMI register

    28.8% of Brighton and Hove (LAD)'s

    998

    COPD register

    Reviews +10.32% in 3 yrs

    Forecast to 2030

    8,575

    Hypertension patients, 2030

    +1,120 on today

    66.2%

    QRISK ≥20% on statins, 2030

    +4.47pp over 3 yrs

    4.0%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    8.6%
    Deprivation and access shortfalls at Wellbn Healthcare.

    Wellbn Healthcare has 8.6% Core20 share, 15.6% QOF vaccination achievement and 36.8% phone access, whereas Charter Medical Centre records 71.0% phone access.

    9.6 pp
    Pre-school booster drop-off and review gaps.

    Age-five MMR coverage drops 9.6 pp from dose 1 (93.4%) to dose 2 (83.8%), and asthma reviews reach 60.5% (England 65.7%).

    +12.0%
    Three-year gains in blood pressure and reviews.

    Under-80 blood pressure control rose +12.0% (England +3.2%), mental health blood pressure checks rose +10.8 pp (England +4.4 pp), and COPD reviews rose +10.3%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    A working-age population of 72.3% may shape demand alongside 1,261 catchment care beds

    Goldstone PCN serves 80,554 registered patients across three practices. Working-age adults aged 18-64 comprise 72.3% of the list (58,280 patients), above Brighton and Hove (71.4%), NHS Sussex ICB (60.5%) and England (62.7%). Older adults aged 65+ account for 12.8% (10,301 patients), below Brighton and Hove (14.0%), NHS Sussex ICB (21.9%) and England (17.9%). Census usual residents in associated areas are 84.8% White (Brighton and Hove 85.4%, NHS Sussex ICB 91.0%, England 81.1%) and 15.2% non-White ethnic minorities, though area Census demographics differ from registered lists. Younger demographics may temper crude chronic disease prevalence, though unverified locally.

    Age profile

    0–1714.9%
    18–6472.3%
    65+12.8%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White84.8%
    Asian5.0%
    Mixed4.9%
    Other3.8%
    Black1.6%

    Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Brighton and Hove LA)2,7022,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)77.9%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)55.1%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA)1,4859819552024/25
    Falls deaths, all ages, per 100,000 (Brighton and Hove LA)19.914.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 3.5% overall but reaches 8.6% at Wellbn Healthcare

    Goldstone PCN has a Core20 cohort of 3.5%, below Brighton and Hove (17.6%), NHS Sussex ICB (9.2%) and England (21.0%), with average IMD decile 6.0. Core20 patients concentrate at Wellbn Healthcare (8.6%, estimated 2,032 patients), versus 1.2% (estimated 303 patients) at Trinity Medical Centre and 1.1% (estimated 343 patients) at Charter Medical Centre. Practice Core20 estimates sum to 2,678, while resident estimates total 2,319. Severe mental illness prevalence is 1.6% (1,333 patients), representing 28.8% of the borough register. Outreach should prioritise the practice with concentrated deprivation.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Wellbn Healthcare8.6% · 2,032 patients
    Trinity1.2% · 303 patients
    Charter1.1% · 343 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    1,333

    SMI register

    1.63% recorded prevalence

    449

    Learning disability register

    0.55% recorded prevalence

    56

    Care homes, 1,261 beds

    In the PCN catchment

    8.2%

    Provide unpaid care

    Brighton and Hove (LAD), Census 2021

    The severe mental illness register records 1,333 patients (1.6%), above Brighton and Hove (1.4%), NHS Sussex ICB (1.1%) and England (1.0%). The learning disability register covers 449 patients (0.6%, in line with England, Brighton and Hove, and NHS Sussex ICB at 0.6%). The PCN catchment includes 56 care homes with 1,261 beds, though beds do not establish registered care-home residents.

    Severe mental illness: physical health checks

    SMI prevalence is 1.6% (England 1.0%). Annual blood pressure checks reach 77.0% (England 83.4%), falling to 70.1% at Charter Medical Centre and 68.1% at Trinity Medical Centre. Recorded BMI is 74.5% (England 82.1%).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,455

    Hypertension register

    +5.70%

    Register growth, 3 yrs

    Brighton and Hove (LAD) +7.27% · England +5.60%

    +6.96pp

    BP control, under 80

    ≤140/90 · +4.90pp aged 80+

    +1,120

    More patients by 2030

    Forecast 8,575 (10.20%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 9.1%, below Brighton and Hove (10.5%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%), though this crude register may reflect a younger demographic. Over three years, blood pressure control under age 80 rose +7.0 pp (England +2.1 pp) to 65.0%, trailing Brighton and Hove (65.3%), the ICB (66.8%) and England (67.8%), and reaching 59.0% at Trinity Medical Centre. For patients aged 80 and over, control is 75.7% (England 81.2%). Recent blood pressure checks stand at 87.3% (England 90.0%). Persistent shortfalls against comparators in blood pressure control across both age bands mean structured treatment escalation should be prioritised.

    Lipids and statins

    Among patients with QRISK ≥ 20%, 56.0% receive lipid-lowering therapy, trailing Brighton and Hove (58.9%), NHS Sussex Integrated Care Board (60.0%) and England (63.6%). Statin treatment for diabetes without cardiovascular disease also lags at 65.1% (England 73.2%). Lower therapy coverage across both indicators suggests an opportunity to audit lipid management.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202680,477£2.70£2.42£1.86£217,288
    Cardiovascular (all), 2025117,728£3.60£3.32£3.33£423,821

    In 2026, the PCN prescribed 80,477 items for lipid-regulating drugs at £2.70 per item, above Brighton and Hove (£2.47), NHS Sussex Integrated Care Board (£2.42) and England (£1.86), spending £67,601 more than at England's unit cost across 80,477 items. Reviewing formulary choices across practices could help identify the drivers of higher unit costs.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +5.64%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +4.30%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 5.9% (England 6.6%) across 4,601 patients, with 60.5% receiving an annual review (England 65.7%), leaving an unreviewed scale of about 1,800 patients. COPD prevalence is 1.2% (England 1.9%) across 998 registered patients; annual review achievement is 67.9% (England 76.4%), despite +10.3% three-year growth (England +2.8%). COPD reviews reach 55.7% at Charter Medical Centre and 77.1% at Wellbn Healthcare. Review shortfalls could reflect recall timing gaps, unverified locally; checking practice recall logs would test it.

    Cancer register and children's immunisation

    The cancer register records 2,372 patients (2.9% prevalence vs 3.8% in England). In childhood immunisations, 6-in-1 at 12 months reaches 94.6% (England 91.0%), but pre-school coverage drops by age 5: MMR dose 2 is 83.8%, trailing dose 1 (93.4%) by 9.6 pp, and 4-in-1 booster coverage is 76.5%, below the 95.0% target by 18.5 pp. Attrition could reflect recall friction, unverified locally; checking call-recall logs would test it.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months94.6%

    England 91.0%

    6-in-1 complete primary course at 24 months91.7%

    England 92.2%

    MMR dose 1 at 24 months88.1%

    England 88.3%

    MMR dose 2 at age 583.8%

    England 82.8%

    4-in-1 pre-school booster at age 576.5%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 (England 55.3%), with a distance of -16.5 pp to the national 75.0% ambition. Reaching that ambition would require about 1,360 extra early-stage diagnoses annually, while known-stage completeness was 64.3% (8,209 of 12,766 registered cancers). Early-stage share rose 5 pp from 2013 to 2022. Goldstone PCN records 62.0% cervical screening coverage aged 25-49 (England 66.8%), falling to 53.7% at Wellbn Healthcare. ICB staging reflects the wider system rather than PCN performance, and unrecorded staging limits interpretation. Screening coverage gaps in primary care coincide with a wider health system that requires substantial.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 19.8 pp (East Sussex Healthcare NHS Trust 67.0%, Surrey and Sussex Healthcare NHS Trust 70.0%, NHS Surrey and Sussex Integrated Care Board 71.5%, England 71.2%). On the 28-day faster diagnosis standard, the trust met 74.0%, trailing the 75.0% standard by 1.0 pp (NHS Surrey and Sussex Integrated Care Board 79.3%, England 79.3%). For diagnostics, 12.9% waited 6+ weeks overall, but colonoscopy reached 39.3% (England 30.8%). Provider performance reflects acute capacity, not PCN delivery.

    Pathways within standard (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)74.0184.2077.7479.2979.32
    31-day treatment (96%)76.7998.1996.2090.4592.50
    62-day referral to treatment (85%)65.2067.0469.9771.5171.16
    Diagnostic waits over 6 weeks (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareEngland
    MRI5.626.4827.5321.40
    CT8.570.4818.499.92
    Echocardiography0.3921.9443.7828.48
    Colonoscopy39.350.7415.1130.83
    Gastroscopy20.020.3121.0629.02
    All 15 DM01 tests12.955.2728.5023.14
    Community services activityBrighton and Hove residentsSurrey and Sussex ICB
    Care contacts23,615309,615
    Referrals5,59066,930
    Patients with a contact7,35085,660

    Community services (residents of Brighton and Hove), Jun 2026 (provisional). In June 2026, Brighton and Hove residents accounted for 23,615 provisional community care contacts and 32,185 care activities, within 309,615 contacts and 316,320 activities across NHS Surrey and Sussex Integrated Care Board. Adults aged 65+ represented 60.7% of borough contacts (14,325 contacts). These experimental figures reflect submitting providers and resident activity rather than unique PCN patients, highlighting strong community service utilisation among older local cohorts.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice access and vaccination achievement vary widely, lagging most sharply at Wellbn Healthcare

    Across 2025/26, QOF clinical achievement was high across all three practices, reaching 100.0% at Wellbn Healthcare, 99.2% at Trinity Medical Centre, and 98.8% at Charter Medical Centre (England 97.1%). However, vaccination and immunisation achievement diverged by 46.6 pp, from 62.2% at Charter Medical Centre to 15.6% at Wellbn Healthcare (England 55.2%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Trinity1081.259.3%75.1%93.2%
    Charter1091.171.0%77.2%89.6%
    Wellbn Healthcare1008.636.8%54.4%67.9%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNBrighton and Hove (LAD)AssetPCNBrighton and Hove (LAD)
    Care homes (catchment)56 (1,261 beds)n/aSchools (catchment)57n/a
    Children's centres614Places of worship57113
    Libraries613Homelessness support (VCS)0no data
    Primary schools (LA maintained)1335Primary academies37
    Special schoolsn/a2

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Across 4,601 asthma patients (5.9% prevalence vs 6.6% in England), 60.5% had a 12-month review (England 65.7%, ICB 62.5%, LAD 60.1%), leaving a scale indicator of 1,818 unreviewed patients (about 1,800). For discussion: run structured recall using a single template alongside flexible review slots and inhaler checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension and lipid therapy escalation

    Hypertension treatment to target is 64.0% (England 70.3%; Trinity Medical Centre under-80 control 59.0%), and QRISK >=20% lipid therapy is 56.0% (England 63.6%). Crude prevalence is 9.1% (7,455 patients; England 15.2%), an unadjusted gap of +1,043 to +4,813. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school immunisation booster catch-up recall

    At age 5 (cohort 136, Q1 2025/26), MMR dose 2 is 83.8% vs 93.4% for dose 1 (9.6 pp difference; Charter Medical Centre 11.1 pp), and 4-in-1 booster is 76.5%, below the 95.0% target by 18.5 pp (ICB 85.8%, England 80.9%). Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Age profile register review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach and triage (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health recall (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall and escalation audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall catch-up (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Targeted cervical screening outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and triage workflow review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension and lipid therapy escalation (p12)Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 3 · Pre-school immunisation booster catch-up recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15